相关实验视频

Updated: Jun 12, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

基于结构的虚拟查发现了新的PKMYT1抑制剂

Haoyu Zhang^1,2,3, Jinyu Yu^1,2,3, Ziheng Yang^1,2,3

¹Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University Shenyang 110016 China medchemzhao@163.com.

RSC medicinal chemistry

|September 23, 2024

概括

天然化合物EGCG,GCG和黄素显示出强大的抑制PKMYT1激酶,这是一个有前途的癌症治疗标. 分子模拟揭示了关键的结合相互作用,指导PKMYT1抑制剂的未来药物开发.

科学领域:

分子生物学分子生物学
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

通过化CDK1-CyclinB.PKMYT1 (WEE家族成员) 对细胞循环调节至关重要.
在瘤学中,PKMYT1激酶是一个有前途的治疗点,特别是考虑到在CCNE1放大时观察到的合成致死性.
目前的PKMYT1抑制剂是有限的,需要发现新的化合物.

研究的目的:

为了确定PKMYT1激酶的新型天然产品抑制剂.
描述已识别的化合物的抑制活性和结合机制.

主要方法:

一个自然产品图书馆的虚拟选.
在体外酶抑制试验测试以确定IC50值.
分子模拟技术用于分析化合物-蛋白相互作用.

主要成果:

EGCG,GCG和黄素显示出强大的PKMYT1抑制,其IC50值分别为0.137μM,0.159μM和1.5μM.
分子模拟确定了DFG地区与Asp251和Glu157的关键键键键,对结合至关重要.
德国德意志联邦地区的约束性相互作用被发现比链和循环区域的更为重要.

结论:

EGCG,GCG和黄素是有效的PKMYT1抑制剂,有可能用于癌症治疗.
了解结合相互作用,特别是在德意志联邦地区,是设计下一代PKMYT1抑制剂的关键.
这些发现为通过抑制PKMYT1.1开发向癌症治疗提供了新的途径.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...